Report Overview
The Global Asthma & COPD Drugs Market size is expected to be worth around USD 64.6 Billion by 2033, from USD 38.2 Billion in 2023, growing at a CAGR of 5.6% during the forecast period from 2024 to 2033.
Asthma and COPD Drugs Market refers to the global industry involved in the research, development, production, and sale of pharmaceuticals and therapeutic treatments designed to manage and treat asthma and chronic obstructive pulmonary disease (COPD). This market encompasses a wide range of medications, including bronchodilators, corticosteroids, leukotriene modifiers, and combination drugs, among others.
The Asthma and COPD Drugs Market has been experiencing significant growth due to the increasing prevalence of respiratory diseases worldwide, driven by factors such as urbanization, pollution, and lifestyle changes. Asthma and COPD are chronic conditions that require ongoing management, creating a steady demand for effective medications. Key players in the market are focusing on innovative treatments, including biologics and combination therapies, to improve patient outcomes and enhance quality of life.
Get a Sample Copy of the Report to Know More https://market.us/report/asthma-copd-drugs-market/request-sample/
Key Market Segments
By Disease type
- COPD
- Asthma
By Medication
- Long-term Asthma Control Medications
- Combination Drugs
- Seretide/Advair
- Symbicort
- Relvar/Breo Ellipta
- Flutiform
- Dulera
- Others
- Anticholinergics
- Spiriva
- Others
- Inhaled Corticosteroids
- Pulmicort
- Flovent
- Qvar
- Others
- Combination Drugs
- Quick-Relief Medications
- Short-acting beta agonists
- Ventolin
- ProAir
- Others
- Ipratropium bromide (Atrovent)
- Oral and Intravenous Corticosteroids
- Others
- Short-acting beta agonists
By Route of Administration
- Inhaled
- Oral
- Others (Intravenous, Subcutaneous)
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacie
You Have Any Questions About This Report, Please Reach Out to Us @
https://market.us/report/asthma-copd-drugs-market/#inquiry
Market Drivers
Prevalence of Asthma and COPD
Global asthma and COPD market is majorly driven by increasing pervasiveness of asthma and chronic obstructive pulmonary disease across the globe. Forming a major disease burden, these diseases leads to declining quality of life and premature death among population. Measured by debility adapted life years, asthma stands at 24th among leading causes of breathing with disability and 34th as the leading cause of disease burden. Thus, the rising cases of asthma and COPD optimistically influences new therapeutics development coupled with escalating ultimatum for asthma and COPD therapeutics globally, thereby resulting in global market excellence.
- According to Asthma and Allergy Foundation of America in June 2020, 1 in 13 Americans suffered from asthma.
- According to Global Disease Burden in 2019, approximately 265 million individuals suffered from asthma in 2019.
Market Restraints
Availability of alternative treatments
Global asthma and COPD drugs market encounters hindrance due to the presence of alternative treatments for treating asthma and chronic obstructive pulmonary disease. The avalibility of non pharmacological options for COPD and asthma such as pulmonary rehabilitation or lifestyle changes can decline the need for medication therapies and thereby decrease market potential for pharmaceutical firms.
Product recalls
Another crucial factor hampering the market growth in recent years include product recalls. Complying with stringent regulatory guidelines and adoption of good manufacturing practices can greatly help to counterbalance the restraint.
- In September 2021, Perrigo Company Plc, recalled Albuterol inhaler, which is utilized to open the airways to treat asthma and other respiratory conditions, due to potential clogging of medical device.
Opportunities
Technological advancements and rising geriatric population offers growth opportunities
The global asthma and COPD drugs market is gaining lucrative opportunities by virtue of rising growth strategies including collaborations and partnerships. For instance, a partnership was established between Phil, Inc. a patient access platform company specializing in life science product commercialization and Teva Pharmaceutical Industries Ltd, an Israel based medical company with the aim to assist patients to receive and refill its Digihaler medication, by launching PhilRx Patient Access Platform.
Another factor contributing towards market success include rising geriatric population more necessitating respiratory illness medications. Advancements in technology coupled with new product launches is further triggering the market growth
- According to World Ageing 2020 estimate, in 2020, the global population was roughly 727 million people aged 65 and above and expected to hike till 1.5 billion by 2050.
- AstraZeneca, a well known pharmaceutical company received approval from European Union for its Trixeo Aerosphere for COPD supportive therapy in December 2020.
Latest Trends
Combination Therapies
The treatment and efficacy of asthma and COPD symptoms notably ameliorated with the formulation of combination therapies. The development of combination therapies include combining of different classes of medications, for example, corticosteroids and bronchodilators, results in a new improvised therapeutic medication.
Immunotherapy
Research and development efforts has led into formation of novel therapeutic options for diverse respiratory conditions. The ongoing research into immunotherapy approaches including anti-inflammatory therapies for COPD and allergen immunotherapy for asthma made ease in providing appropriate and safe medications for patients dealing with COPD and asthma.
Impact of Macroeconomic Factors
Globalization & Economy Likely to Influence Market Growth
Globalization in the form of international trade and supply chain dynamics highly influences the availability and pricing of asthma and COPD medications. The expense of asthma treatments in diverse market is affected by the changes occurring in trade policies, currency exchange rates and tariffs. In addition to these, the severity of asthma coupled with its prevalence is also influenced by environmental factors such as climate change, allergen exposure, and air pollution.
The hike in these concerns demands for advanced asthma and COPD treatments, especially in high pollution level containing regions. And lastly, growth in economy impacts the overall purchasing power of patients combined with healthcare spending capacity. Higher the economic growth, more is the inclination towards medical care including asthma and COPD treatment, thereby demanding medications, devices and healthcare services, leading to growth in market reach.
Contact Us :
420 Lexington Avenue, Suite 300 New York City, NY 10170,
United States
Phone: +1 718 618 4351 (International),+91 78878 22626 (Asia)
Email: inquiry@market.us
